Inbiomotion appoints Ralf van den Berg as Chief Operating Officer

Ralf van den Berg will lead the development and execution of Inbiomotion's strategy while managing daily operations.  In his new role, Ralf van den Berg will drive Inbiomotion in his aim to position MAFTEST® for routine characterization of breast cancer tumors.